10 powodów, dla których warto stosować lisinopril Artykuł przeglądowy
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
gru 31, 2016
Słowa kluczowe:
inhibitory ACE, lisinopril, nadciśnienie tętnicze
##plugins.themes.bootstrap3.article.main##
Abstrakt
Inhibitory konwertazy angiotensyny (ACE-I) to jedna z podstawowych grup leków stosowanych w chorobach układu sercowo-naczyniowego. Jednym z najlepiej przebadanych jej przedstawicieli jest lisinopril. Ma on wiele unikalnych cech, które powodują, że jest on niezwykle przydatny klinicznie. W Polsce wskazaniami do jego stosowania są: nadciśnienie tętnicze (zarówno w monoterapii, jak i w leczeniu skojarzonym), niewydolność serca czy m.in. choroba niedokrwienna serca w ostrej fazie zawału serca. Pojawiło się jednak wiele nowych doniesień, które w nieodległej przyszłości mogą się przyczynić do poszerzenia wskazań do stosowania właśnie tego inhibitora ACE.
##plugins.themes.bootstrap3.article.details##
Jak cytować
Dąbrowska, D., & Mamcarz , A. (2016). 10 powodów, dla których warto stosować lisinopril. Medycyna Faktów , 9(4(33), 307-312. Pobrano z https://journalsmededu.pl/index.php/jebm/article/view/2203
Numer
Dział
Artykuły
Copyright © by Medical Education. All rights reserved.
Bibliografia
1. Januszewicz A., Januszewicz W., Rużyłło W.: Inhibitory konwertazy angiotensyny w leczeniu chorób układu sercowo-naczyniowego. Medycyna Praktyczna, Kraków 2009.
2. Tykarski A., Narkiewicz K., Gaciong Z. et al.: Zasady postępowania w nadciśnieniu tętniczym – 2015 rok. Wytyczne Polskiego Towarzystwa Nadciśnienia Tętniczego. Nadciśn. Tętn. 2011; 15: 55-82.
3. Terpstra W.F., May J.F., Smit A.J. et al.: Effects of amlodipine and lisinopril on intima-media thickness in previously untreated, elderly hypertensive patients (the ELVERA trial). J. Hypertens. 2004; 22: 1309-1316.
4. Malacco E., Santonastaso M., Vari N.A. et al.; Blood Pressure Reduction and Tolerability of Valsartan in Comparison with Lisinopril Study: Comparison of valsartan 160 mg with lisinopril 20 mg, given as monotherapy or in combination with a diuretic, for the treatment of hypertension: the Blood Pressure Reduction and Tolerability of Valsartan in Comparison with Lisinopril (PREVAIL) study. Clin. Ther. 2004; 26: 855-865.
5. Lancaster S.G., Todd P.A.: Lisinopril. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure. Drugs 1988; 35: 646-669.
6. Poldermans D., Glazes R., Kargiannis S. et al.: Tolerability and blood pressure-lowering efficacy of the combination of amlodipine plus valsartan compared with lisinopril plus hydrochlorothiazide in adult patients with stage 2 hypertension. Clin. Ther. 2007; 29: 279-289.
7. Mancia G., Zanchetti A., Agabiti-Rosei E. et al.: Ambulatory blood pressure is superior to clinic blood pressure in predicting treatment-induced regression of left ventricular hypertrophy. SAMPLE Study Group. Study on Ambulatory Monitoring of Blood Pressure and Lisinopril Evaluation. Circulation 1997; 95: 1464-1470.
8. Farsang C.; HAMLET Trial Investigation: Advantages of lisinopril amlodipine fixed combination therapy in hypertension. A comparative study of the efficacy and tolerability of amlodipine 5 mg and lisinopril 10 mg administered separately and in combination in hypertension. Hypertonia es Nephrologia 2004; 8: 72-78.
9. Farsang C., Abraham G., Kovacs P. et al.: The effectivity and safety of Amlodipin-Lisinopril Fix-combination in patients with ESSential hypertension (ALFESS Study). Hypertonia es Nefrologia 2009; 13: 81-87.
10. Mancia G., Grassi G.: Antihypertensive effects of combined lisinopril and hydrochlorothiazide in elderly patients with systodiastolic or systolic hypertension: results of a multicenter trial. J. Cardiovasc. Pharmacol. 1997; 30: 548-553.
11. Zuanetti G., Latini R., Maggioni A.P. et al.: Effect of the ACE inhibitor lisinopril on mortality in diabetic patients with acute myocardial infarction: data from the GISSI-3 study. Circulation 1997; 96: 4239-4245.
12. Chaturvedi N., Sjolie A.K., Stephenson J.M. et al.: Efect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. EUCLID Study Group. EURODIAB Controlled Trial of Lisinopril in Insulin-Dependent Diabetes Mellitus. Lancet 1998; 351: 28-31.
13. Cushman W.C., Davis B.R., Pressel S.R. et al.: Mortality and morbidity during and after the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. J. Clin. Hypertens. (Greenwich) 2012; 14: 20-31.
14. Barzilay J.I., Davis B.R., Cutler J.A. et al.: Fasting Glucose Levels and Incident Diabetes Mellitus in Older Nondiabetic Adults Randomized to Receive 3 Different Classes of Antihypertensive Treatment: A Report From the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch. Intern. Med. 2006; 166(20): 2191-2201.
15. Potter J.F., Robinson T.G., Ford G.A. et al.: Controlling Hypertension, and hypotension immediately post-stroke (CHHIPS): a randomised, placebo- controlled, double-blind pilot trial. Lancet Neurology 2009; 8: 48-56.
16. Massie B.M., Armstrong P.W., Cleland J.G. et al.: Toleration of high doses of angiotensin-converting enzyme inhibitors in patients with chronic heart failure: results from the ATLAS trial. Assessment of Treatment with Lisinopril and Survival. Arch. Intern. Med. 2001; 161: 165-171.
17. Boden W.E., O’Rourke R.A., Teo K.K. et al.: Optimal medical therapy with or without PCI for stable coronary disease. New. Engl. J. Med. 2007; 356: 1503-1516.
18. Mogensen C.E., Neldam S., Tikkanen I. et al.: Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ 2000; 321: 1440-1444.
19. Menne J., Farsang C., Deák L. et al.: Valsartan in combination with lisinopril versus the respective high dose monotherapies in hypertensive patients with microalbuminuria: the VALERIA trial. J. Hypertens. 2008; 26: 1860-1867.
20. Goadsby P.J., Sprenger T.: Aktualne postępowanie i kierunki na przyszłość w profilaktyce i leczeniu doraźnym napadów migreny (tłum. z j. ang.). Neur. Prakt. 2011; 11(4): 47-64.
21. Solfrizzi V., Scafato E., Frisardi V et al.: Angiotensin-converting enzyme inhibitors and incidence of mild cognitive impairment. The Italian Longitudinal Study on Aging. Age 2013; 35: 441-453.
22. Ponikowski P., Voors A.A., Anker S.D. et al.: 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur. Heart J. 2016; 37: 2129-2200.
2. Tykarski A., Narkiewicz K., Gaciong Z. et al.: Zasady postępowania w nadciśnieniu tętniczym – 2015 rok. Wytyczne Polskiego Towarzystwa Nadciśnienia Tętniczego. Nadciśn. Tętn. 2011; 15: 55-82.
3. Terpstra W.F., May J.F., Smit A.J. et al.: Effects of amlodipine and lisinopril on intima-media thickness in previously untreated, elderly hypertensive patients (the ELVERA trial). J. Hypertens. 2004; 22: 1309-1316.
4. Malacco E., Santonastaso M., Vari N.A. et al.; Blood Pressure Reduction and Tolerability of Valsartan in Comparison with Lisinopril Study: Comparison of valsartan 160 mg with lisinopril 20 mg, given as monotherapy or in combination with a diuretic, for the treatment of hypertension: the Blood Pressure Reduction and Tolerability of Valsartan in Comparison with Lisinopril (PREVAIL) study. Clin. Ther. 2004; 26: 855-865.
5. Lancaster S.G., Todd P.A.: Lisinopril. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure. Drugs 1988; 35: 646-669.
6. Poldermans D., Glazes R., Kargiannis S. et al.: Tolerability and blood pressure-lowering efficacy of the combination of amlodipine plus valsartan compared with lisinopril plus hydrochlorothiazide in adult patients with stage 2 hypertension. Clin. Ther. 2007; 29: 279-289.
7. Mancia G., Zanchetti A., Agabiti-Rosei E. et al.: Ambulatory blood pressure is superior to clinic blood pressure in predicting treatment-induced regression of left ventricular hypertrophy. SAMPLE Study Group. Study on Ambulatory Monitoring of Blood Pressure and Lisinopril Evaluation. Circulation 1997; 95: 1464-1470.
8. Farsang C.; HAMLET Trial Investigation: Advantages of lisinopril amlodipine fixed combination therapy in hypertension. A comparative study of the efficacy and tolerability of amlodipine 5 mg and lisinopril 10 mg administered separately and in combination in hypertension. Hypertonia es Nephrologia 2004; 8: 72-78.
9. Farsang C., Abraham G., Kovacs P. et al.: The effectivity and safety of Amlodipin-Lisinopril Fix-combination in patients with ESSential hypertension (ALFESS Study). Hypertonia es Nefrologia 2009; 13: 81-87.
10. Mancia G., Grassi G.: Antihypertensive effects of combined lisinopril and hydrochlorothiazide in elderly patients with systodiastolic or systolic hypertension: results of a multicenter trial. J. Cardiovasc. Pharmacol. 1997; 30: 548-553.
11. Zuanetti G., Latini R., Maggioni A.P. et al.: Effect of the ACE inhibitor lisinopril on mortality in diabetic patients with acute myocardial infarction: data from the GISSI-3 study. Circulation 1997; 96: 4239-4245.
12. Chaturvedi N., Sjolie A.K., Stephenson J.M. et al.: Efect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. EUCLID Study Group. EURODIAB Controlled Trial of Lisinopril in Insulin-Dependent Diabetes Mellitus. Lancet 1998; 351: 28-31.
13. Cushman W.C., Davis B.R., Pressel S.R. et al.: Mortality and morbidity during and after the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. J. Clin. Hypertens. (Greenwich) 2012; 14: 20-31.
14. Barzilay J.I., Davis B.R., Cutler J.A. et al.: Fasting Glucose Levels and Incident Diabetes Mellitus in Older Nondiabetic Adults Randomized to Receive 3 Different Classes of Antihypertensive Treatment: A Report From the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch. Intern. Med. 2006; 166(20): 2191-2201.
15. Potter J.F., Robinson T.G., Ford G.A. et al.: Controlling Hypertension, and hypotension immediately post-stroke (CHHIPS): a randomised, placebo- controlled, double-blind pilot trial. Lancet Neurology 2009; 8: 48-56.
16. Massie B.M., Armstrong P.W., Cleland J.G. et al.: Toleration of high doses of angiotensin-converting enzyme inhibitors in patients with chronic heart failure: results from the ATLAS trial. Assessment of Treatment with Lisinopril and Survival. Arch. Intern. Med. 2001; 161: 165-171.
17. Boden W.E., O’Rourke R.A., Teo K.K. et al.: Optimal medical therapy with or without PCI for stable coronary disease. New. Engl. J. Med. 2007; 356: 1503-1516.
18. Mogensen C.E., Neldam S., Tikkanen I. et al.: Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ 2000; 321: 1440-1444.
19. Menne J., Farsang C., Deák L. et al.: Valsartan in combination with lisinopril versus the respective high dose monotherapies in hypertensive patients with microalbuminuria: the VALERIA trial. J. Hypertens. 2008; 26: 1860-1867.
20. Goadsby P.J., Sprenger T.: Aktualne postępowanie i kierunki na przyszłość w profilaktyce i leczeniu doraźnym napadów migreny (tłum. z j. ang.). Neur. Prakt. 2011; 11(4): 47-64.
21. Solfrizzi V., Scafato E., Frisardi V et al.: Angiotensin-converting enzyme inhibitors and incidence of mild cognitive impairment. The Italian Longitudinal Study on Aging. Age 2013; 35: 441-453.
22. Ponikowski P., Voors A.A., Anker S.D. et al.: 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur. Heart J. 2016; 37: 2129-2200.